NasdaqGS:RGNX

Stock Analysis Report

Executive Summary

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease.

Snowflake

Fundamentals

High growth potential with excellent balance sheet.

Risks

  • REGENXBIO has significant price volatility in the past 3 months.

Similar Companies

Share Price & News

How has REGENXBIO's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

5.2%

RGNX

1.0%

US Biotechs

-0.6%

US Market


1 Year Return

-42.5%

RGNX

-10.8%

US Biotechs

0.6%

US Market

RGNX underperformed the Biotechs industry which returned -11.4% over the past year.

RGNX underperformed the Market in United States of America which returned 1.1% over the past year.


Share holder returns

RGNXIndustryMarket
7 Day5.2%1.0%-0.6%
30 Day13.8%-0.7%2.2%
90 Day-25.0%-1.8%1.1%
1 Year-42.5%-42.5%-10.1%-10.8%2.9%0.6%
3 Year173.5%173.5%5.8%2.2%44.6%35.2%
5 Yearn/a3.8%-1.2%61.9%44.2%

Price Volatility Vs. Market

How volatile is REGENXBIO's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is REGENXBIO undervalued based on future cash flows and its price relative to the stock market?

19%

Discount to future cash flow value


Intrinsic Value Based on Future Cash Flows

REGENXBIO's share price is below the future cash flow value, but not at a moderate discount (< 20%).

REGENXBIO's share price is below the future cash flow value, but not at a substantial discount (< 40%).


Price Based on Earnings

REGENXBIO is loss making, we can't compare its value to the US Biotechs industry average.

REGENXBIO is loss making, we can't compare the value of its earnings to the United States of America market.


Price Based on Expected Growth

Unable to calculate PEG ratio for REGENXBIO, we can't assess if its growth is good value.


Price Based on Value of Assets

REGENXBIO is overvalued based on assets compared to the US Biotechs industry average.


Next Steps

Future Growth

How is REGENXBIO expected to perform in the next 1 to 3 years based on estimates from 5 analysts?

72.1%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

REGENXBIO's revenue is expected to grow significantly at over 20% yearly.

REGENXBIO's earnings are expected to grow significantly at over 20% yearly.

REGENXBIO's revenue growth is expected to exceed the United States of America market average.

REGENXBIO's earnings growth is expected to exceed the United States of America market average.

REGENXBIO's earnings growth is expected to exceed the low risk savings rate of 2.7%.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if REGENXBIO will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.


Next Steps

Past Performance

How has REGENXBIO performed over the past 5 years?

20.6%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

REGENXBIO does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.

Unable to compare REGENXBIO's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare REGENXBIO's 1-year growth to the US Biotechs industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if REGENXBIO has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

It is difficult to establish if REGENXBIO has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if REGENXBIO improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is REGENXBIO's financial position?


Financial Position Analysis

REGENXBIO is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

REGENXBIO's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

REGENXBIO has no debt.

REGENXBIO currently has no debt however we can't compare to 5 years ago as we have no data for that period.


Balance Sheet

Low level of unsold assets.

REGENXBIO has no debt, it does not need to be covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

REGENXBIO has sufficient cash runway for more than 3 years based on current free cash flow.

Unable to confirm if REGENXBIO has at least 1 year of cash runway based on growing free cash flows without relevant data.


Next Steps

Dividend

What is REGENXBIO's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate REGENXBIO's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate REGENXBIO's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as REGENXBIO has not reported any payouts.

Unable to verify if REGENXBIO's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as REGENXBIO has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of REGENXBIO's salary, the management and board of directors tenure and is there insider trading?

2.8yrs

Average management tenure


CEO

Ken Mills (44yo)

10.5yrs

Tenure

US$4,938,199

Compensation

Mr. Kenneth T. Mills, also known as Ken, has been the Chief Executive Officer and President at REGENXBIO Inc. since March 2009. Mr. Mills served as the Chief Financial Officer and Vice President of Busines ...


CEO Compensation Analysis

Ken's remuneration is about average for companies of similar size in United States of America.

Ken's compensation has increased whilst company is loss making.


Management Age and Tenure

2.8yrs

Average Tenure

49.5yo

Average Age

The tenure for the REGENXBIO management team is about average.


Board Age and Tenure

4.4yrs

Average Tenure

65.5yo

Average Age

The tenure for the REGENXBIO board of directors is about average.


Insider Trading

No 3 month open market individual insider trading information.


Ownership Breakdown


Management Team

  • Curran Simpson (57yo)

    Senior VP of Product Development & Chief Technology Officer

    • Tenure: 4.1yrs
    • Compensation: US$1.90m
  • Ram Palanki

    Senior VP of Commercial Strategy & Operations

    • Tenure: 1.1yrs
  • Patrick Christmas (48yo)

    Senior VP & General Counsel

    • Tenure: 3.1yrs
  • Ken Mills (44yo)

    CEO, President & Director

    • Tenure: 10.5yrs
    • Compensation: US$4.94m
  • Vit Vasista (51yo)

    Chief Financial Officer

    • Tenure: 10.1yrs
    • Compensation: US$1.94m
  • Olivier Danos (61yo)

    Chief Scientific Officer

    • Tenure: 2.5yrs
    • Compensation: US$1.61m
  • Stephen Yoo (41yo)

    Consultant

    • Tenure: 0.8yrs
    • Compensation: US$1.88m
  • Laura Coruzzi

    Senior Vice President of Intellectual Property

    • Tenure: 3.3yrs
  • Andrew Yost

    Vice President of Corporate Development

    • Tenure: 2.5yrs
  • Shiva Fritsch

    Senior Vice President of Human Resources

    • Tenure: 1.9yrs

Board Members

  • Don Hayden (63yo)

    Chairman of the Board

    • Tenure: 6.6yrs
    • Compensation: US$470.58k
  • Dave Stump (69yo)

    Independent Director

    • Tenure: 3.9yrs
    • Compensation: US$442.08k
  • Dan Abdun-Nabi (64yo)

    Independent Director

    • Tenure: 3.1yrs
    • Compensation: US$438.08k
  • Jerry Karabelas (67yo)

    Independent Director

    • Tenure: 4.3yrs
    • Compensation: US$438.58k
  • Inder Verma (71yo)

    Member of Scientific Advisor

    • Tenure: 0yrs
  • Luke Beshar (60yo)

    Independent Director

    • Tenure: 4.4yrs
    • Compensation: US$450.58k
  • Allan Fox (71yo)

    Director

    • Tenure: 10.6yrs
    • Compensation: US$430.58k
  • Judith Swain (70yo)

    Member of Scientific Advisor

    • Tenure: 0yrs
  • Daniel Tassé (59yo)

    Independent Director

    • Tenure: 3.1yrs
    • Compensation: US$435.58k
  • Ken Mills (44yo)

    CEO, President & Director

    • Tenure: 10.5yrs
    • Compensation: US$4.94m

Company Information

REGENXBIO Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: REGENXBIO Inc.
  • Ticker: RGNX
  • Exchange: NasdaqGS
  • Founded: 2008
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$1.469b
  • Shares outstanding: 36.81m
  • Website: https://www.regenxbio.com

Number of Employees


Location

  • REGENXBIO Inc.
  • 9600 Blackwell Road
  • Suite 210
  • Rockville
  • Maryland
  • 20850
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
RGNXNasdaqGS (Nasdaq Global Select)YesCommon SharesUSUSDSep 2015
RB0DB (Deutsche Boerse AG)YesCommon SharesDEEURSep 2015

Biography

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic p ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/21 00:24
End of Day Share Price2019/09/20 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.